Navigation Links
CROI -- Day 3: Selected highlights of NIH-supported research
Date:3/1/2011

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

iPrEx Update

Robert M. Grant, M.D., of the J. David Gladstone Institutes in San Francisco, presented an update on the results of the iPrEx study. As reported in November 2010, this placebo-controlled clinical trial found that daily oral Truvada (tenofivir plus emtricitabine) was safe and 44 percent effective at preventing HIV infection in the nearly 2,500 HIV-negative gay and bisexual men and transgender women in the trial.

iPrEx Bone Density Study

Kathleen Mulligan, Ph.D., of the University of California, San Francisco, presented the findings of the DEXA study, which examined the effects of daily oral Truvada on bone mineral density using data from a subgroup of 503 participants enrolled in the iPrEx study. The DEXA study found small but significant decreases in bone mineral density among the individuals who took daily Truvada compared with those who took a placebo pill. Given the known association between tenofovir and decreases in the bone mineral density of HIV-infected individuals taking this antiretroviral therapy, the new finding can help scientists begin to determine whether the cause of the observed effect on bone mass is tenofovir, the virus, a host-virus interaction or other factors.

Monkey Studies of Innate Immunity

Vanessa Hirsch, D.V.M., D.Sc., of NIAID in Bethesda, Md., described how variations in the TRIM5 gene affect the level of simian immunodeficiency virus (SIV), the monkey counterpart of HIV, in rhesus macaques infected with sooty mangabey-derived SIV (SIVsm). SIVsm is a strain commonly used in animal model studies of vaccine candidates. Rhesus macaques can have five different forms of TRIM5 that vary in the degree to which they control virus replication. Dr. Hirsch reported how variations in the TRIM5 protein potentially influence the observed protective effects of vaccine candidates tested in rhesus macaques that are challenged with SIVsm.


'/>"/>

Contact: Laura Sivitz Leifman
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Nurse-Attorney/Former Bristol-Myers Squibb Executive Selected To Lead New Jersey State Nurses Association
2. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
3. The Icebox of Atlanta Selected as T-shirt Vendor for 3 Major Divisions of American Cancer Society's Relay For Life
4. Nurtur Is Selected By Keenan & Associates as Exclusive Provider of Disease Management Programs
5. Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program
6. Rajesh Khanna, MD Selected as One of America's Top Ophthalmologist
7. DC Dermatologist Dr. Susan T. Elliott Selected Best Doctor by Washingtonian Magazine
8. PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest
9. Dr. Rajesh Khanna Selected as Best Lasik Surgeon Two Years in a Row
10. R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting
11. Phoseon Technology Selected as Finalist for 2010 TechAmerica Oregon Technology Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia ... Summary GlobalData,s new report, "Australia Glaucoma Surgery ... data on the Australia Glaucoma Surgery Devices market. ... dollars, volume (in units) and average prices (USD) ... The report also provides company shares and distribution ...
Breaking Medicine Technology: